SNUH researchers publish world's 1st RWD on Lixiana
Korean researchers have published the first-ever real-world study on a novel oral anticoagulant (NOAC) in the Journal of the American College of Cardiology on Aug. 21.
The study focused on Lixiana (edoxaban), a NOAC developed by Daiichi Sankyo, and real-world data (RWD) refers to data obtained from the clinical field, not through large-scale clinical trials.
The study is the world’s first real-world study on Lixiana that examines the safety and efficacy of the non-vitamin K antagonist oral anticoagulant. It marks the first time researchers published RWD related to Asians rather than Westerners in NOAC.
The team, led by SNUH Professors Choi Eue Keun and Lee So-ryoung, evaluated the safety and efficacy of Lixiana compared to warfarin in Korean patients with nonvalvular atrial fibrillation.
For more details, please see, http://www.koreabiomed.com/news/articleView.html?idxno=4039